P. J. Lachmann - Concepedia

Author

P. J. Lachmann

Also Known As

P J LACHMANN, P J Lachmann, P J. Lachmann, P LACHMANN, P Lachmann, P. J. LACHMANN, P. J. Lachmann, P. LACHMANN, P. Lachmann, P.J Lachmann

246

Publications

10.2K

Citations

H-Index

185

Concepts

All Affiliations

University of Cambridge MRC Epidemiology Unit Medical Research Council MRC Laboratory of Molecular Biology MRC Cancer Unit

About

P. J. Lachmann is an author at University of Cambridge specializing in medicine, immunology, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	83	5.4K
2	Health Sciences	11	12	676
3	Natural Sciences	7	7	535
4	Law	1	1	20
5	Public Health	1	1	152

P. J. Lachmann

129

Publications

8.7K

Citations

H-Index

Page 1

	Year	Citations
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. Alun Davies, David L. Simmons, G Hale, The Journal of Experimental Medicine ImmunohematologyCd59 AntigenLaboratory ImmunologyImmunologyImmunodominance	1989	639
Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. G D Ross, William J. Yount, Mark Walport, The Journal of Immunology	1985	300
REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS P. J. Lachmann, R. A. Thompson The Journal of Experimental Medicine ImmunologyMolecular BiologyReactive LysisChemical BiologyProtein Purification	1970	271
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures Sheena McHugh, Ian R. Rifkin, John Deighton, Clinical & Experimental Immunology	1995	263
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. Mark Wing, T. Moreau, Judith Greenwood, Journal of Clinical Investigation First-dose Cytokine-release SyndromeImmunologyImmune RegulationNk CellsImmunologic Mechanism	1996	254
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell Yasuhiro Takeuchi, François–Loïc Cosset, P. J. Lachmann, Journal of Virology Viral ReplicationImmunologyViral PathogenesisPathologyProducer Cell	1994	231
Safety and efficacy of xenon in routine use as an inhalational anaesthetic P. J. Lachmann The Lancet Routine UseMedicineAnesthesia PracticeToxicologyInhalational Anaesthetic	1990	229
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions Yara Maria Lucisano-Valim, P. J. Lachmann Clinical & Experimental Immunology	1991	202
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Seppo Meri, Herman Waldmann, P. J. Lachmann PubMed	1991	198
REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS R. A. Thompson, P. J. Lachmann The Journal of Experimental Medicine ImmunologyReactive LysisProtein PurificationBioanalysisHematology	1970	196

Page 1